3 patents have been granted to scientists from MUB in cooperation with scientists from the Siedlce University of Natural Sciences and Humanities and the Medical University of Lublin:
- Patent No. 237893, the authors of which are: prof. dr hab. Anna Bielawska, prof. dr hab. Krzysztof Bielawski, prof. dr hab. Dariusz Pawlak, dr Justyna Hermanowicz, dr hab. Anna Tankiewicz-Kwedlo, mgr Anna Szymanowska from the Medical University of Białystok, dr hab. Mariusz Mojzych from the Siedlce University of Natural Sciences and Humanities and dr Katarzyna Kotwica-Mojzych from the Medical University of Lublin
- Patent No. 237894, the authors of which are: prof. dr hab. Anna Bielawska, prof. dr hab. Krzysztof Bielawski, mgr Wojciech Szymanowski from the Medical University of Białystok, dr hab. Mariusz Mojzych from the Siedlce University of Natural Sciences and Humanities and dr Katarzyna Kotwica-Mojzych from the Medical University of Lublin
- Patent No. 237895, the authors of which are: prof. dr hab. Anna Bielawska, prof. dr hab. Krzysztof Bielawski from the Medical University of Białystok, dr hab. Mariusz Mojzych from the Siedlce University of Natural Sciences and Humanities and dr Katarzyna Kotwica-Mojzych from the Medical University of Lublin.
The present invention relates to compounds with a sulfonamide moiety, the chemical structure of which differs from that of conventionally used anti-cancer drugs. Patent protection covers both the method of their production and their use in the treatment of breast and colon cancer - the two most frequently diagnosed neoplasms.
On the part of MUB, a research team led by prof. Anna and Krzysztof Bielawski and the team of prof. Dariusz Pawlak from the Faculty of Pharmacy.
In the face of steadily increasing morbidity and mortality due to neoplastic diseases, research centers around the world are constantly looking for effective treatment strategies. An attractive therapeutic approach is targeted therapy, tailored to the patient's needs, which precisely and targeted destroys cancer cells.
The proposed solution, which is the result of cooperation between scientists from the centers in Białystok, Siedlce and Lublin, fits in with the above strategy.
All three molecules show high anti-tumor activity in vitro. Advanced preclinical studies of the MM129 compound, which has a high safety profile in the range of therapeutic doses used, are currently underway.
Further work may constitute the basis for the development of innovative methods of oncological therapy that will improve the effectiveness and safety of treatment of patients.
